158 related articles for article (PubMed ID: 36257285)
1. Genetic Variants in Histone Modification Regions Predict Clinical Outcomes of Pemetrexed Chemotherapy in Lung Adenocarcinoma.
Lee YH; Do SK; Lee SY; Kang HG; Choi JE; Hong MJ; Lee JH; Lee S; Lee WK; Jeong JY; Shin KM; Park JE; Choi SH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Oncology; 2023; 101(2):96-104. PubMed ID: 36257285
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.
Frost N; Zhamurashvili T; von Laffert M; Klauschen F; Ruwwe-Glösenkamp C; Raspe M; Brunn M; Ochsenreither S; Temmesfeld-Wollbrück B; Suttorp N; Grohé C; Witzenrath M
Clin Lung Cancer; 2020 Nov; 21(6):e607-e621. PubMed ID: 32620471
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in histone modification regions are associated with the prognosis of lung adenocarcinoma.
Kang HG; Lee YH; Lee SY; Choi JE; Do SK; Hong MJ; Lee JH; Jeong JY; Do YW; Lee EB; Shin KM; Lee WK; Choi SH; Seo HW; Yoo SS; Lee J; Cha SI; Kim CH; Cho S; Jheon S; Park JY
Sci Rep; 2021 Nov; 11(1):21520. PubMed ID: 34728688
[TBL] [Abstract][Full Text] [Related]
4. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
[TBL] [Abstract][Full Text] [Related]
5. [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung
Adenocarcinoma].
Li P; Li B; Shi Y; Zhang F; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2019 Mar; 22(3):137-142. PubMed ID: 30909992
[TBL] [Abstract][Full Text] [Related]
6. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study.
Jun N; Hanping W; Xiaoyan S; Yan X; Mengzhao W; Xiaotong Z; Li Z
Thorac Cancer; 2020 Jul; 11(7):1869-1875. PubMed ID: 32406994
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
He P; Wang Y; Yang S; Yu S; Wang Z; Li J; Wang B; Hao X; Wang H; Hu X; Zhang X; Shi Y
Zhongguo Fei Ai Za Zhi; 2013 Oct; 16(10):529-34. PubMed ID: 24113006
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
Fukuda M; Kitazaki T; Ogawara D; Ichiki M; Mukae H; Maruyama R; Nakagaki N; Shimada M; Ikeda T; Kishimoto J; Harada T; Seto T; Ebi N; Takayama K; Okamoto I; Ichinose Y; Sugio K
Lung Cancer; 2019 Jun; 132():1-8. PubMed ID: 31097081
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study.
Lou Y; Xu J; Zhang Y; Lu J; Chu T; Zhang X; Wang H; Zhong H; Zhang W; Han B
Target Oncol; 2020 Apr; 15(2):175-184. PubMed ID: 32170554
[TBL] [Abstract][Full Text] [Related]
10.
Hong MJ; Park JE; Lee SY; Lee JH; Choi JE; Kang HG; Do SK; Jeong JY; Shin KM; Lee WK; Seok Y; Choi SH; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
J Cancer; 2022; 13(15):3701-3709. PubMed ID: 36606188
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
Lu Z; Ye M; Sun T; Wu S; Lin Z; Zhang X; Rao D; Zhang D; Ke Y; Chen Z
Ann Palliat Med; 2022 Jun; 11(6):2100-2109. PubMed ID: 35817745
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
[TBL] [Abstract][Full Text] [Related]
13. An expression quantitative trait locus variant for LKB1 gene predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer.
Seo H; Jung DK; Kang HG; Jeong JY; Lee SY; Choi JE; Hong MJ; Do SK; Lee JH; Lee WK; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Cancer Genet; 2018 Dec; 228-229():73-82. PubMed ID: 30553476
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
Niho S; Yoshida T; Akimoto T; Sakamaki K; Ono A; Seto T; Nishio M; Yamamoto N; Hida T; Okamoto H; Kurata T; Satouchi M; Goto K; Yamanaka T; Ohe Y
Lung Cancer; 2020 Mar; 141():64-71. PubMed ID: 31955002
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
[TBL] [Abstract][Full Text] [Related]
16. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Yang JC; Hirsh V; Schuler M; Yamamoto N; O'Byrne KJ; Mok TS; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist LV
J Clin Oncol; 2013 Sep; 31(27):3342-50. PubMed ID: 23816967
[TBL] [Abstract][Full Text] [Related]
17. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W
Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967
[TBL] [Abstract][Full Text] [Related]
18. Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma.
Wang JN; Qiao QH; Hu XS; Liu YT; Wang ZJ; Duan JC; Feng Y; Zhu HH
Chin Med J (Engl); 2021 Jun; 134(17):2119-2121. PubMed ID: 34133351
[No Abstract] [Full Text] [Related]
19. Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes.
Wang JL; Tsai YT; Lin CH; Cidem A; Staniczek T; Chang GR; Yen CC; Chen W; Chong KY; Chen CM
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439918
[TBL] [Abstract][Full Text] [Related]
20. [Association between the ALK Gene Status and the Efficacy of First-line
Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].
Chen M; Cao H; Ji Y; Mao Y; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):732-736. PubMed ID: 29167001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
